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Abstract  30 
Raynaud’s phenomenon (RP) is characterised by recurrent transient peripheral vasospasm 31 
and lower nitric oxide (NO) bioavailability in the cold. We investigated the effect of nitrate-32 
rich beetroot juice (BJ) supplementation on i) NO-mediated vasodilation, ii) cutaneous 33 
vascular conductance (CVC)  and  skin temperature (Tsk) following  local cooling and iii) 34 
systemic anti-inflammatory status. 35 
Following baseline testing, twenty-three individuals with RP attended four times, in a double-36 
blind, randomized crossover design, following acute and chronic (14 days) BJ and nitrate-37 
depleted beetroot juice (NDBJ) supplementation. Peripheral Tsk and CVC were measured 38 
during and after mild hand and foot cooling, and during transdermal delivery of acetylcholine 39 
and sodium nitroprusside. Markers of anti-inflammatory status were also measured.  40 
Plasma [nitrite] was increased in the BJ conditions (P < 0.001). Compared to the baseline 41 
visit, thumb CVC was greater following chronic-BJ (Δ2.0 fluxꞏmmHg-1, P = 0.02) and 42 
chronic-NDBJ (Δ1.45 fluxꞏmmHg-1, P = 0.01) supplementation; however, no changes in Tsk 43 
were observed (P > 0.05). Plasma [interleukin-10] was greater, pan endothelin and systolic 44 
and diastolic blood pressure (BP) were reduced, and forearm endothelial function was 45 
improved ,by both BR and NDBJ supplementation (P < 0.05).  46 
Acute and chronic BJ and NDBJ supplementation improved  anti-inflammatory status, 47 
endothelial function and BP. CVC following cooling increased post chronic-BJ and chronic-48 
NDBJ supplementation, but no effect on Tsk was observed. 49 
Key points  50 
Beetroot supplementation improves 51 
1) thumb blood flow,52 
2) anti-inflammatory status,53 
3) endothelial function and54 
4) reduces BP55 





New and noteworthy 60 
This is the first study to examine the effect of dietary nitrate supplementation in individuals 61 
with Raynaud’s phenomenon. The principal novel findings from this study were that both 62 
beetroot juice and nitrate depleted beetroot juice: 1) increased blood flow in the thumb 63 
following a cold challenge; 2) enhanced endothelium-dependant and -independent 64 
vasodilation in the forearm; 3) reduced systolic and diastolic blood pressure, and [pan-65 
endothelin]; and 4) improved inflammatory status in comparison to baseline. 66 
67 
1.0 Introduction  68 
Raynaud’s phenomenon (RP) is characterized by recurrent transient vasospasm of the fingers 69 
and/or toes in response to a cold or stressful stimulus (66) which causes discomfort and pain. 70 
Administration of NO donors, such as the organic nitrate, Glyceryl Trinitrate (GTN), can 71 
improve blood flow in those with cold sensitivity (32) and RP (1). Reduced NO 72 
bioavailability has been implicated in the aetiology of RP. Although GTN can improve blood 73 
flow in RP (1), chronic GTN administration produces a tolerance and diminishing 74 
vasodilatory effect (54). Moreover, organic nitrates (i.e. GTN and isosorbide mononitrate) 75 
can provoke deleterious side effects, such as headaches (66). Alternative long-term therapies 76 
to improve blood flow in RP warrant investigation.  77 
Topical application of inorganic nitrate on the forearm and fingers of individuals with RP can 78 
increase blood flow (64) and may counter the vasoconstrictor effects of the endothelins which 79 
are elevated in RP (10). Leafy green vegetables and beetroot have a particularly high 80 
concentration of inorganic nitrate (8) and their vasodilatory effects can improve 81 
cardiovascular health (24). Dietary inorganic nitrate supplementation has been shown to 82 
improve skin blood flow (48) and microvascular function (39), and to lower blood pressure 83 
(BP) in healthy individuals (68) and those with hypertension (39), peripheral arterial disease 84 
(41) and heart failure (69). Promisingly, oral ingestion of inorganic nitrate does not appear to85 
cause the same side effects or tachyphylaxis (57) reported for organic nitrates. 86 
The efficacy of dietary inorganic nitrate supplementation is considered NO-mediated and 87 
evoked through the stepwise reduction of nitrate to nitrite, and finally, nitrite to NO (52). 88 
After oral consumption dietary inorganic nitrate is absorbed into the circulation, concentrated 89 
in the saliva and converted to nitrite via anaerobic bacteria on the dorsum of the tongue (15). 90 
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This nitrite is then swallowed (4) and absorbed into the circulation, where it acts as a storage 91 
pool for subsequent NO production. The reduction of nitrite to NO is expedited in conditions 92 
of acidosis and hypoxia (13), as seen in the digital vasculature in RP (66). The entero-salivary 93 
pathway is considered a complementary system for NO synthesis (50), which becomes 94 
increasingly important when the nitric oxide synthase (NOS) system is deficient, such as 95 
when individuals with RP are exposed to the cold (62). 96 
Consumption of beetroot juice (BJ) can lower BP to a greater extent than an equimolar dose 97 
of an inorganic nitrate salt (36), suggesting that other components of BJ might interact with 98 
nitrate to elicit additive or synergistic effects on vascular function. The antioxidant (67) 99 
properties of BJ may be important, as attenuated NO-mediated vasodilation in inflammatory 100 
conditions is partly due to elevated oxidative stress (21, 49, 65). As RP is characterized by 101 
systemic oxidative stress and inflammation (6, 29), BJ may have a beneficial effect by 102 
increasing both NO and antioxidants. (21). BJ may therefore offer an inexpensive and safe 103 
intervention to reduce oxidative stress and inflammation, to enhance peripheral blood flow 104 
and rewarming, and to mitigate pain following a local cold challenge in RP. 105 
This study investigated the effects of acute and chronic BJ and nitrate-depleted BJ (NDBJ) 106 
supplementation on 1) cutaneous blood flow, rewarming and pain sensation following a local 107 
cold challenge, 2) inflammatory biomarkers and, 3) endothelium-dependant and -independent 108 
vasodilation and BP in individuals with RP. We hypothesised that, compared to NDBJ, BJ 109 
would increase plasma [nitrate] and [nitrite], lower inflammation, and improve BP, 110 
endothelium-dependant and -independent vasodilation, cutaneous vascular conductance 111 
(CVC) and peripheral skin rewarming following a local cold challenge. 112 
113 
2.0 Methods  114 
2.1 Participants 115 
Individuals were recruited if they had primary or secondary RP, were at least 18 years old 116 
and were willing and able to provide consent for participation in the study. Individuals were 117 
excluded if they had known renal impairment (estimate of glomerular filtration rate < 30); 118 
uncontrolled hypertension; were taking organic nitrates, nicorandil, or thiazolidinidiones; had 119 
experienced a myocardial or cerebrovascular event in the previous 3 months; were a current 120 
5 
smoker (any smoking event within the last 3 months) or if they had any other serious medical 121 
condition which would interfere with data interpretation or participant safety. Participants 122 
taking phosphodiesterase inhibitors were asked to refrain from using them for the duration of 123 
the study. Mouthwash was prohibited for the duration of the study and for at least 1 week 124 
prior to the first visit as reduction in the oral microflora is known to alter nitrate metabolism 125 
(27). Additionally, participants were asked to avoid caffeine and alcohol for 3 and 24 hours 126 
prior to testing, respectively. Finally, participants were asked to record what they ate prior to 127 
each visit and replicate this where possible for the 24 hours before arriving at the laboratory 128 
for subsequent testing. 129 
Twenty-seven participants were recruited (see Table 1) from a clinical database of individuals 130 
with RP from the Rheumatology Department, Queen Alexandra Hospital (Portsmouth, UK). 131 
Posters, word of mouth and local interest groups were also targeted for recruitment. All 132 
participants provided written informed consent and their flow through the trial is shown in 133 
Figure 1. A favourable ethics opinion was granted by the Hampshire B NRES Committee 134 
(17/SC/0148) and this double-blind, randomised, cross-over trial was registered on the 135 
ClinicalTrials.gov website, ID # NCT03129178. 136 
137 
2.2 Pre-experimental tests 138 
Following enrolment into the study, a letter was sent to each participant’s General 139 
Practitioner (GP), to inform them of their participation within the trial. Participants who did 140 
not want their GP informed (n = 1) were provided with the GP letter. Participants were given 141 
the opportunity to ask any questions they may have after reading the participant information 142 
sheet. A standard medical history and clinical examination was undertaken, which included 143 
height, body mass, ankle-brachial pressure index and venous blood samples. Seated resting 144 
BPs (6 on each arm, mean of last 3 recorded) were performed using an automated BP monitor 145 
(Omron M5, Omron, Milton Keynes, UK). Participants then undertook a test of 146 
microvascular endothelial function (iontophoresis) in an ambient temperature of 23°C, 147 
followed by a cold challenge in an ambient temperature of 30°C (both described below) as 148 
baseline measures. 149 
During the first visit, concealed allocation was used by an independent researcher to 150 
randomise participants to begin either the BJ or NDBJ arm of the study. Specifically, a 151 
computer programme (www.randomizer.org) was utilised to randomly allocate study numbers 152 
to treatment order. The appropriate bottles of BJ were placed in a sealed opaque envelope. 153 
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Participants were then provided with instructions and their first acute dose to take away with 154 
them. It was estimated that twenty-five individuals with RP were needed to achieve a 155 
moderate to large effect size in a pilot study (30). Therefore, we aimed to recruit 30 156 
individuals with RP to account for a 15% drop-out rate. 157 
158 
2.3 Protocol and outcome measures 159 
For visits 2 and 4 (the acute supplementation visits), participants were instructed to ingest an 160 
acute dose of 140 mL of either BJ (delivering 12.4 mmol of inorganic nitrate) or NDBJ 161 
(NDBJ; delivering 0.1 mmol of inorganic nitrate (Beet It, James Whites Drinks Ltd.) one and 162 
a half hours before arriving at the laboratory. We previously reported that both the BJ and 163 
NDBJ have similar antioxidants and polyphenol content (59). On arrival at the laboratory, 164 
participants rested for 10 minutes. Resting seated BP was then measured 5 times, with the 165 
mean of the last 3 recorded. A ~ 20 mL venous blood sample was then drawn from the 166 
antecubital fossa. The iontophoresis derived measures of microvascular endothelial function 167 
conducted at baseline were then repeated in ambient conditions (23°C), followed by a cold 168 
challenge in an ambient temperature of 30°C (both described below). Visits 3 and 4 (after the 169 
crossover period) were separated by at least 7 days to allow washout and all visits were 170 
conducted at the same time of day (± 1 hour) in a counter-balanced order.  171 
Visits 3 and 5 (the chronic supplementation visits) were identical in nature to visits 2 and 4, 172 
however followed chronic supplementation of 70 mLꞏday-1 of either BJ or NDBJ for 13 days 173 
with 140 mL consumed on the day of testing. Participants, if requested, were reminded to 174 
take the juice via text message or voice mails. 175 
2.4 Outcome measures 176 
Our primary outcome measure was change in cutaneous blood flow and rewarming following 177 
a local cold challenge. Secondary outcome measures included, endothelium-dependant and -178 
independent vasodilation, pain, inflammatory biomarkers and BP.  179 
Microvascular endothelial function test 180 
Individuals were acclimated for a minimum of 30 minutes in an ambient temperature of 23.2 181 
± 0.4ºC prior to acetylcholine (ACh) and sodium nitroprusside (SNP) being delivered 182 
transdermally via iontophoresis to three sites in the following order: 1) volar aspect of the left 183 
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forearm, 2) middle phalanx of the middle finger of the left hand, and 3) dorsal aspect of the 184 
left foot as previously described (17).  185 
Briefly, following cleaning of the skin surface with water for injection, two perspex rings 186 
were attached to the skin with one acting as an anode, and the other as the cathode. These 187 
electrodes were connected to the iontophoresis controller (MIC 2, Moor Instruments, UK). 188 
Both chambers had an 8 mm inner diameter. The anode chamber was filled with ~ 0.5 mL of 189 
ACh (Braun, Melsungen, Germany), with a 1% concentration dissolved in water for injection. 190 
The cathode chamber was filled with ~ 0.5 mL of SNP (Sigma-aldirch, Missouri, USA) with 191 
a 0.01% concentration dissolved in water for injection. The protocol for electrical pulses 192 
included: four at 25 μA, followed by a single pulse of 50 μA, 100 μA, 150 µA and 200 µA. 193 
These pulses lasted for 20 s with 120 s intervals between each pulse where no current was 194 
applied. An interval of five minutes was given between testing each site (forearm, finger and 195 
foot).  196 
Laser doppler probes (VP1T / 7, Moor Instruments, UK), connected to a perfusion monitor 197 
(moor VMS-LDF, Moor Instruments, UK) were used to assess skin blood flow. Data were 198 
recorded using an acquisition system (Powerlab, AD Instruments, Australia) and software 199 
(LabChart 7, AD Instruments, Australia). The laser doppler probes were secured in the 200 
Perspex rings prior to the iontophoresis protocol on the forearm, finger, dorsal foot and on the 201 
corresponding site on the contra-lateral limb (to differentiate between local and systemic 202 
responses). Skin blood flow responses were expressed as CVC (CVC = skin flux/MAP; 203 
flux.mmHg-1). The average skin blood flow for both ACh and SNP was calculated over the 204 
final 20 s of the intervals between each successful pulse (i.e. 100-120 s post each pulse) (17). 205 
Maximal skin blood flow, taken at the highest point which was not always following the final 206 
pulse and area under the curve (AUC) were calculated for each participant. Skin temperature 207 
(Tsk) was recorded with skin thermistors (Grants Instruments, Cambridge) placed next to the 208 
Perspex chambers. BP was measured on the contra-lateral arm to the site of iontophoresis 209 
using an automated BP monitor (Omron M5, Omron, Milton Keynes, UK) before and after 210 
each iontophoresis protocol to calculate mean arterial pressure (MAP).   211 
Cold sensitivity test 212 
The cold sensitivity test used in this study has been comprehensively described elsewhere 213 
(17). Testing took place in a climatic controlled chamber at an air temperature of 29.6 ± 214 
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0.87°C. Participants were asked to remove their shoes and socks, and rest in a semi- 215 
recumbent position for 15 minutes. Those capable of cycling (n = 20) were asked to cycle on 216 
an ergometer (Tunturi, T6, Turku, Finland) between 20 and 50 W for 12 minutes as this has 217 
been shown to improve the reliability of the test by removing central vasoconstrictor tone 218 
(18). Participants were then asked to rest in a semi-recumbent position for a minimum of 5 219 
minutes while resting toe temperature and blood flow were recorded.  220 
The participants placed their foot (n=21/23 right foot) into a plastic bag (to keep it dry) and 221 
immersed into 15.02 ± 0.01°C water to the point of their mid-malleoli for 2 minutes. 222 
Following the immersion period, the bag was removed and the rate of toe skin rewarming and 223 
blood flow were recorded while the participant was semi-recumbent. This procedure was then 224 
repeated on the hand (mean temperature; 14.95 ± 0.02°C: n = 22/23 right hand), following 5 225 
minutes seated rest. During the rewarming the arm was supported. 226 
Skin blood flow was assessed using a laser Doppler probe (VP1T / 7, Moor Instruments, UK) 227 
secured to the Great toe pads during foot immersion and on the pads of the thumbs during 228 
hand immersion. Analysis of skin blood flow was conducted using minute averages before, 229 
during and after immersion (i.e. rewarm period) and expressed as CVC. CVC was analysed 230 
between conditions at the following time points: pre immersion, and during 5 and 10 minutes 231 
of rewarming following removal from the water. 232 
Tsk was measured using an infrared camera (A320G, FLIR systems, UK) and in accordance 233 
with the protocol described by Moreira, Costello, Brito, Adamczyk, Ammer, Bach, Costa, 234 
Eglin, Fernandes and Fernández-Cuevas (53). The camera lens was positioned 1.0 m away 235 
from the sole of the participant’s foot and the palm of the hand and the spot analysis function 236 
on the FLIR software (FLIR systems, UK) was used to analyse the surface temperature on the 237 
pads of the toes / fingers immediately prior to immersion and at the end of each minute 238 
during the 10 minute re-warm. The thumb, mean finger (mean of all 5), great toe, mean toe 239 
and coldest toe Tsk were analysed between conditions and across time at multiple time points: 240 
pre-immersion and 5 and 10 minute into the rewarming period. Within our laboratory, the 241 
coefficient of variation for the cold sensitivity test for finger and toe Tsk is 2.7% and 8.7%, 242 
respectively (17). MAP was calculated from BP measured using an automated blood pressure 243 
monitor (Omron M5, Milton Keynes, UK) on the left arm prior to each immersion and 244 
following both rewarming periods. 245 
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Both thermal comfort and sensation were measured using a 20 cm scale (0 = very 246 
cold/uncomfortable; 10 = neutral; 20 = very hot/comfortable; modified from Zhang, 247 
Huizenga, Arens and Wang (70)) and recorded prior to immersion, during immersion and 248 
every 2 minutes of the rewarming period. Pain sensation was assessed using a numerical 249 
rating scale for pain (0 no pain, 10 unimaginable, unspeakable pain; (19)) at the same time 250 
points. 251 
2.5 Biochemical analysis 252 
Venous blood (and saliva where blood could not be taken, n = 2) samples were taken and 253 
processed prior to testing on each study visit. Blood samples for plasma [nitrate] and [nitrite] 254 
were taken in Lithium Heparin tubes and ethylenediaminetetraacetic acid tubes for 255 
assessment of oxidative stress and inflammatory markers. The blood and saliva samples were 256 
placed in a chilled (4oC) centrifuge and spun at 4500 g for 10 minutes immediately following 257 
collection. Once spun, the plasma and saliva was pipetted into aliquots with a link 258 
anonymised code. The samples were then placed in a -80oC freezer until subsequent analysis. 259 
Plasma and saliva samples were analysed for [nitrate] and [nitrite] using a Sievers NO analyser 260 
(Sievers NOA 280i, Analytix Ltd. Durham, UK), via a modification of the ozone 261 
chemiluminescence technique previously described by Bateman, Ellis and Freeman (3). 262 
Plasma [peroxiredoxin-4] and [thioredoxin-1] were quantified using in-house ELISAs 263 
developed using commercially available antigens and antibodies (Abcam, Cambridge). The 264 
human SOD3 antigen and rabbit antiserum directed against human [superoxide dismutase-3] 265 
were developed as previously described (26). A cytometric bead array technique was used to 266 
quantify plasma interleukin (IL)-6 and IL-10 on a BD C6 Accuri Flow Cytometer (BD 267 
Biosciences, Berkshire, UK). [Pan endothelin] was quantified using commercially available 268 
DuoSet ELISA kits (R&D Systems, Abingdon, UK).   269 
2.6 Qualitative analysis  270 
Semi-structured interviews were conducted to examine the acceptability of the supplement 271 
and the testing procedures. Specifically, semi-structured interviews explored participants’ 272 
experiences of the study procedures and consumption of BJ. At the time of the interviews, 273 
both the interviewer and participants were still blinded to the treatment order.  A total of ten 274 
semi-structured interviews were necessary to reach a point of data saturation (i.e., where no 275 
new information was provided by the participants). Interviews were conducted by a 276 
researcher with experience in qualitative research methods. Interviews were recorded, 277 
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transcribed verbatim, and analysed through thematic analysis as outlined by Braun and 278 
Clarke (7). A deductive process was used throughout the analysis, where transcripts were 279 
reviewed and direct quotations were used to establish initial codes for each question posed. 280 
Codes were then grouped together to create themes based on identified similarities. Coding of 281 
transcripts relied on a reflexive process, where themes were constantly compared to initial 282 
codes and the data set as a whole. 283 
2.7 Data analysis  284 
As previously reported with iontophoresis (17), some individuals had high skin resistance 285 
which meant that not all pulses could be delivered to the forearm, fingers and feet. Where 286 
participants had incomplete data sets (current response curves), the number of pulses 287 
analysed was the same within individual for each visit (17).  288 
The distribution of data was assessed using descriptive methods (skewness, outliers, and 289 
distribution plots) and inferential statistics (Shapiro–Wilk test). Where normal distribution 290 
was violated non parametric analyses were performed. For the cold sensitivity test, statistical 291 
differences were assessed using 5 × 3 repeated-measures ANOVAs (condition [baseline, 292 
acute BJ, chronic BJ, acute NDBJ and chronic NDBJ supplementation] * time [pre 293 
immersion, 5 min, 10 min]) for mean toe, coldest toe, great toe, mean finger, coldest finger 294 
and thumb Tsk, thumb and great toe skin blood flows. For the endothelial function test, 295 
maximum CVC, AUC and Tsk were analysed using repeated-measures ANOVAs (baseline, 296 
acute BJ, chronic BJ, acute NDBJ and chronic NDBJ supplementation). Plasma [nitrate] and 297 
[nitrite] were analysed using repeated measures ANOVA and all other biomarkers were 298 
analysed using Friedman tests. Where appropriate, post-hoc tests were conducted using 299 
pairwise comparisons with least significant differences. Where data were not normally 300 
distributed Friedman tests were used with Wilcoxon follow ups. Data are presented as mean 301 
(SD) or as median and 25th and 75th percentiles unless otherwise stated. Statistical analysis 302 
was performed on SPSS version 24 (Chicago, IL) and statistical difference and trends 303 
towards significance were accepted as 2-tailed P < 0.05 and P < 0.1 respectively. Interviews 304 




Twenty-seven individuals consented to take part in the trial and twenty-three completed the 308 
study. A detailed analysis of participant recruitment and withdrawal, is shown in Figure 1. 309 
We report 5 adverse events. Of the 4 participants who withdrew, 1 withdrew to relocate for 310 
work, 1 reported hot flushes and 2 reported nausea and sickness (all outside of the 311 
laboratory). One of these adverse events was related to the intervention and the other two 312 
may have been related to the intervention. Two participants reported gastrointestinal distress 313 
which was tolerable for the duration of the study. Participant-reported adherence to the 314 
supplementation protocol was excellent, with only one participant reporting missing one day 315 
during the chronic supplementation period. All participants reported avoiding mouthwash 316 
during the testing periods. Numerous participants reported red stools and beeturia as with 317 
previous studies (17, 58-60). The full data set for this trial has been made available on our 318 
University repository (https://doi.org/10.17029/f9c6af22-d8f5-4989-9cf1-1422b9467010).  319 
3.1 Plasma [nitrate] and [nitrite] 320 
Supplementation with BJ significantly increased plasma [nitrate] (P < 0.001; Figure 2), and 321 
[nitrite] (P < 0.001; Figure 2). Post-hoc analysis revealed a statistically significant rise in 322 
plasma [nitrate] between acute NDBJ and acute BJ supplementation (43 ± 25 µM; 339 ± 146 323 
µM; P < 0.001, respectively) and chronic NDBJ and chronic BJ supplementation (52 ± 29 324 
µM; 397 ± 96 µM; P < 0.001, respectively) and plasma [nitrite] between acute NDBJ and 325 
acute BJ supplementation (69 ± 23 nM; 428 ± 187 nM; P < 0.001, respectively) and chronic 326 
NDBJ and chronic BJ supplementation (87 ± 31 nM; 428 ± 117 nM; P < 0.001, respectively) 327 
(Figure 2). There were no differences between acute and chronic NDBJ (P > 0.05) and acute 328 
and chronic BJ (P > 0.05).  329 
3.2 Cold sensitivity test  330 
A significant difference in CVC was observed between the visits for supplement (P = 0.01), 331 
time (P = 0.01), but not their interaction (P = 0.52) in the thumb (see figure 3, B). Follow-up 332 
tests revealed increased thumb CVC between baseline and chronic NDBJ (2.0 flux.mmHg-1, 333 
P = 0.02) and chronic BJ (1.45 flux.mmHg-1, P = 0.01). Chronic supplementation resulted in 334 
a greater thumb CVC than acute supplementation for both the NDBJ (1.9 flux.mmHg-1, P = 335 
0.03) and BJ (1.3 flux.mmHg-1, P = 0.01; see figure 3, B) conditions. No differences were 336 
seen in the great toe CVC (all P ≥ 0.05; see figure 3, A).  337 
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Tsk of the toes (great toe, coldest toe and mean toe temperature) and fingers (thumb, coldest 338 
finger and mean finger temperature) was not altered by acute or chronic supplementation 339 
with BJ or NDBJ (P > 0.05 for all comparisons; Figures 3C and 3D). Tsk of the toes and 340 
fingers were not different when split for disease type (data not shown, P > 0.05).  341 
Thermal comfort, sensation and pain  342 
There were no differences in thermal sensation, thermal comfort or pain sensation for the 343 
hand at any time point during the cold sensitivity test between visits (P < 0.05). In the foot, 344 
there were no differences between conditions for thermal sensation or pain sensation at any 345 
time point. Although thermal comfort was similar prior to immersion, it was perceived 346 
differently during immersion (P < 0.05), immediately after immersion (P = 0.004) and during 347 
rewarming (P = 0.02). During immersion, participants reported feeling more thermally 348 
comfortable in the baseline condition compared to the acute-NDBJ (P = 0.04; Table 2) and 349 
chronic-BJ supplementation conditions (P = 0.006; Table 2). Thermal comfort was also 350 
greater following acute- compared to chronic-NDBJ supplementation (P = 0.001) during 351 
immersion. Immediately after immersion, participants felt less thermal comfort compared to 352 
baseline in all the other conditions (acute NDBJ; P = 0.003, acute BJ; P = 0.03, chronic 353 
NDBJ; P = 0.002, and chronic BJ; P = 0.002; Table 2). During the rewarming phase, the 354 
baseline condition was reported as more thermally comfortable than either the acute NDBJ (P 355 
= 0.03; Table 2) or the chronic BJ (P = 0.008; Table 2) conditions. 356 
3.3 Microvascular endothelial function 357 
Endothelial-dependant and -independent function was significantly different between the 358 
visits for supplement in the forearm for ACh Max (P = 0.05), SNP Max (P = 0.02) and SNP 359 
AUC (P = 0.03) but not ACh AUC (P = 0.21). Post-hoc tests revealed that, compared to 360 
baseline, acute-BJ increased CVC with ACh (Max, P = 0.02) and chronic-BJ increased CVC 361 
with SNP (Max, P = 0.05). Chronic-BJ supplementation was also found to significantly 362 
increase CVC with SNP (Max, P = 0.001; and AUC, P = 0.02) compared to NDBJ. Trends 363 
towards a significant increase in CVC compared to baseline were also seen with chronic-BJ 364 
with ACh (max P = 0.07) and SNP (AUC, P = 0.09) and acute-NDBJ with SNP (AUC, P = 365 
0.08).  366 
The responses to ACh and SNP were similar during all five visits on the finger (ACh Max, P 367 
= 0.67; ACh AUC, P = 0.84; SNP Max, P = 0.80; SNP AUC; P = 0.95) and foot (ACh Max, 368 
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P = 0.10; ACh AUC , P = 0.25; SNP Max, P = 0.21; SNP AUC, P = 0.52). See figures 4 and 369 
5 respectively. 370 
3.4 BP 371 
Systolic and diastolic BP were different across time (SBP; P < 0.001, DBP; P < 0.001). 372 
Compared to acute NDBJ, acute BJ significantly reduced systolic BP (127 ± 16 mmHg vs. 373 
121 ± 16 mmHg, P = 0.01) and diastolic BP (77 ± 8 mmHg vs. 74 ± 7 mmHg; P = 0.03). This 374 
effect was not present with chronic supplementation for either systolic BP (NDBJ: 122 ± 15 375 
mmHg; BJ: 121 ± 16 mmHg, P = 0.43) or diastolic BP (NDBJ: 75 ± 8 mmHg; BJ: 74 ± 8 376 
mmHg, P = 0.49). Compared to baseline, both NDBJ and BJ reduced systolic BP (acute 377 
NDBJ: 8.0 ± 11 mmHg, P = 0.02; acute BJ: 13.6 ± 10.8 mmHg, P < 0.001; chronic NDBJ, 12 378 
± 14 mmHg,  P < 0.001; and chronic BJ: 14 ± 11 mmHg,  P < 0.001) and diastolic BP (acute 379 
NDBJ: 6 ± 8 mmHg,  P = 0.02; acute BJ, 9 ± 7 mmHg,  P < 0.001; chronic NDBJ: 8 ± 9 380 
mmHg, P < 0.001; and chronic BJ: 9 ± 7 mmHg, P < 0.001) see figure 6.  381 
3.5 Cytokines and redox markers 382 
[Pan endothelin] was reduced after supplementation with BJ (P = 0.03; Figure 7A). Acute 383 
NDBJ (P = 0.01) and BJ (P = 0.04) resulted in higher [pan endothelin] compared to baseline. 384 
There was a trend for an increase with chronic NDBJ (P = 0.07) but not chronic BJ (P = 0.18; 385 
Figure 7A). BJ supplementation altered plasma concentrations of the anti-inflammatory 386 
cytokine, IL-10 (P < 0.001; Figure 7B) with IL-10 increasing in all four experimental 387 
conditions compared to baseline (acute NDBJ P < 0.001; acute BJ, P < 0.001; chronic-NDBJ, 388 
P = 0.001; and chronic-BJ, P = 0.002; Figure 7B) but did not alter IL-6 (P = 0.97; Figure 5C) 389 
between conditions. Plasma [SOD3], (P = 0.18; Figure 5D), TRX-1, (P = 0.11; Figure 7E) 390 
and PRDX-4 (P = 0.28; Figure 7F) did not differ between visits. IL-10 was significantly 391 
higher than baseline for all time points for primary but not secondary RP ((P < 0.001) data 392 
not shown).  393 
3.6 Qualitative interviews 394 
Semi-structured exit interviews were conducted with 10 participants. Several recruitment 395 
strategies were used (as described in the methods section) and participants recommended that 396 
similar strategies be used to recruit participants in the future with the additional use of social 397 
media suggested for future trials. Most participants (n = 20) experienced symptoms of RP in 398 
their hands, with three individuals stating that they felt greater discomfort in their feet. 399 
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Overall, participants said that the study was a positive experience. One participant indicated 400 
the BJ made her feel ill. However, this participant decided to continue with the study and did 401 
not withdraw. None of the participants were sure they had felt any positive health benefits as 402 
a result of the juice, during any of the sessions. One participant indicated she felt as though 403 
the juice "...opened up her blood vessels" but this was deemed as neither a positive nor 404 
negative reaction to the juice. Most participants did not enjoy drinking the juice, with only 405 
one participant indicating that he enjoyed it. Participants mentioned the juice had an 406 
unpleasant taste, with some individuals complaining it tasted metallic, too sweet and had a 407 
thick composition. Despite the negative reaction to the juice, most individuals indicated they 408 
simply adjusted to the juice. Nearly all individuals said they would wait to find out the results 409 
of the study before purchasing the juice or discussing it with other individuals. One 410 




This is the first study to examine the effect of dietary nitrate supplementation in individuals 415 
with RP. Specifically, we examined the effects of supplementation with BJ on  cutaneous 416 
blood flow, rewarming and pain sensation following a local cold challenge, and inflammatory 417 
biomarkers, antioxidant enzymes, endothelium-dependant and -independent vasodilation, and 418 
BP in individuals with RP compared to baseline and NDBJ. The principal novel findings 419 
from this study were that 1) both BJ and NDBJ increased blood flow in the thumb following 420 
a cold challenge; 2) enhanced endothelium-dependant and -independent vasodilation in the 421 
forearm; 3) reduced systolic BP, diastolic BP and [pan-endothelin]; and 4) improved 422 
inflammatory status in comparison to baseline. These findings suggest acute and chronic BJ 423 
and NDBJ supplementation have the potential to reduce inflammatory status and improve 424 
aspects of vascular function in individuals with RP.   425 
4.1 Plasma [nitrate] and [nitrite] 426 
Plasma [nitrate] and [nitrite] were elevated following acute and chronic BJ supplementation 427 
compared to NDBJ. This elevation in circulating plasma [nitrite] represents an increase in the 428 
potential for nitric oxide synthase (NOS) independent NO generation, with NOS-dependent 429 
NO generation attenuated in conditions of increased oxidative stress (21, 49, 65) such as in 430 
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RP (6, 29). Hypoxic and acid environments are known to increased conversion of nitrite to 431 
NO (13), and since the digital vasculature is more hypoxic and acidic in RP (1) increased 432 
plasma [nitrite] following BJ supplementation had the potential to increased blood flow and 433 
re-warming compared to NDBJ. 434 
4.2 Cold sensitivity test  435 
In individuals with cold sensitivity, acute BJ does not improve skin temperature or blood flow 436 
in the hands or feet (17). However, an increased skin blood flow in the thumb in individuals 437 
with RP following chronic supplementation of BJ and NDBJ was observed in the current 438 
study. No effect in the feet was observed, which may at least in part be due to divergent 439 
mechanisms of vascular control in the hands and feet (55). Thumb skin blood flow was 440 
higher prior to immersion and stayed higher during and following immersion in both chronic 441 
supplementation protocols indicating this effect is likely due to the antioxidant content of 442 
beetroot as opposed nitrate content of BJ and the elevations in [nitrate] and [nitrite] given the 443 
comparable responses in the BJ and NDBJ conditions. Indeed, some antioxidant and 444 
polyphenol compounds found in the BJ/NDBJ have previously been shown to have 445 
vasodilatory properties such as chlorogenic acid (56); quercetin (16); caffeic acid (45) and 446 
this may at least in part explain why we see changes in blood flow in both types of juice. The 447 
observed improvement in skin blood flow did not however translate into increased skin 448 
temperature. Although the increase in skin temperature following the cold challenge is due to 449 
cutaneous blood flow in healthy controls, individuals with poor peripheral blood flow rewarm 450 
passively in a warm environment (14). Therefore, it could be that, although CVC was 451 
increased in the small area under the laser doppler probe, the overall increase in skin blood 452 
flow was not large enough to translate into a statistical or clinically meaningful change in 453 
skin temperature (i.e. 0.5ºC ) (2).  454 
4.3 Thermal comfort, sensation and pain 455 
Neither BJ or NDBJ altered thermal sensation or comfort in the hand or feet during the cold 456 
sensitivity test, which is similar to previous findings in cold sensitive individuals (17). 457 
Thermal comfort of the foot was however, reduced during cooling and in the subsequent 458 
rewarming period following BJ supplementation, despite Tsk being the same. Since thermal 459 
comfort was not altered prior to immersion, BJ may have altered the perception of cooled 460 
skin though not to a level where increased pain was reported. Thermal sensation and 461 
particularly thermal comfort are subjective and some participants struggled to decide on a 462 
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number to report, especially when their foot was numb. The apparent decrease in comfort 463 
could be a function of being more familiar with the scales and therefore being able to respond 464 
more promptly at a time of dynamic activation of the cutaneous thermoreceptors which is 465 
critical for perception of comfort (14). Given CVC increased in the thumb and thermal 466 
sensation was not worse there could be a site-specific effect that is linked to alterations in 467 
blood flow. Most participants reported RP symptoms in the hands and not their feet, so an 468 
increased CVC in the hand with no changes in thermal sensation maybe a positive outcome, 469 
however this warrants further investigation. 470 
4.4 Endothelial function 471 
Individuals with RP exhibit cutaneous microvascular dysfunction which manifests as reduced 472 
finger blood flow in all environmental conditions compared to controls (28). Some of this 473 
dysfunction is due to impaired endothelium dependent vasodilation (43). The effect of nitrate 474 
supplementation on endothelial function has been examined in numerous cohorts such as 475 
healthy individuals (48), cold sensitive (17), obese (37), type 2 diabetes mellitus (25), and has 476 
been reviewed elsewhere (46). The dose appears to be important (46), however comparison 477 
of acute vs chronic supplementation has yet to be examined in any population. Neither BJ nor 478 
NDBJ altered microvascular endothelial function in the fingers or the foot. However, 479 
improvements in endothelium-independent (SNP) and -dependent (ACh) vasodilation were 480 
observed in the forearm following chronic BJ supplementation. Potential explanations for the 481 
change in SNP-induced smooth muscle cell function following chronic supplementation 482 
could be due to a suppression in eNOS derived NO (11) and or nitrite mediated inhibition of 483 
NADPH derived superoxide, leading to increased bioavailability of NO (22). Collectively, 484 
such effects might explain the enhanced responsiveness to the exogenous NO donor, SNP. 485 
Collectively, such effects might explain the enhanced responsiveness to an exogenous NO 486 
donor. Chronic BJ also increased cutaneous vasodilation in the forearm to ACh 487 
administration when compared to chronic NDBJ, suggesting that the elevated nitrite, NO 488 
and/or their intermediates may have evoked additional vasodilatory effects from those 489 
elicited by the antioxidants in BJ. Improvements in forearm arm blood flow suggest that the 490 
effects of BJ and NDBJ are systemic (31). Iontophoresis on the foot and fingers was not 491 
always possible due to high skin resistance meaning that the sample size was compromised, 492 
which may explain why no effect was observed at these sites. Conversely, it may be that 493 
nitrite levels were not increased sufficiently to improve digital microvascular function. 494 
However, given the increased blood flow following hand cooling this seems implausible. 495 
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Endothelins are a family of peptides, which cause vasoconstriction and thus antagonise the 496 
actions of NO. Although acute BJ and NDBJ reduced plasma concentrations of pan-497 
endothelin compared to baseline (Figure 5) chronic BJ and NDBJ did not alter plasma [pan-498 
endothelin] which suggests that divergent mechanisms may underpin changes in endothelial 499 
function after acute and chronic BJ and NDBJ supplementation. RP is associated with 500 
elevated [endothelin-1] (10), which can lead to chronic pain (61) and may also explain why 501 
endothelial function is impaired (38). However, our cohort do did not appear to have 502 
impaired endothelial function at baseline compared to healthy controls (17). Therefore, we 503 
cannot preclude a larger effect in individuals with overt endothelial dysfunction. Our cohort 504 
however, self-reported high levels of physical activity (4.3 ± 2.5 bouts of >30 min per week). 505 
Regular exercise which is a key stimulus for promoting endogenous NO production via shear 506 
stress induced activation of endothelial NOS  (9). This may explain, in part, why additional 507 
nitrate via the entero-salivary pathway failed to show an additional benefit between BJ vs. 508 
NDBJ, and perhaps a more sedentary cohort of participants may have benefited. IL-10, on the 509 
other hand, increased across all time points and, therefore, may play a larger role in mediating 510 
the changes in vascular function after acute and chronic BJ and NDBJ supplementation in 511 
individuals with RP. 512 
 4.5 Blood pressure 513 
The present data also demonstrated a reduction in both systolic and diastolic BP in all 514 
conditions compared to baseline. To our knowledge, this is the first study to demonstrate that 515 
NDBJ can reduce BP. Explanations for this reduction in BP are multifactorial. A well-516 
recognised phenomenon of BP trials is that BP appears to fall across time, and as such 517 
caution should be taken with interpreting these findings. However, there are other active 518 
ingredients in BJ, including antioxidants and polyphenols (59, 67) such as, batalins, gallic 519 
acid, chlorogenic acid and quercetin (see Shepherd, Wilkerson, Dobson, Kelly, Winyard, 520 
Jones, Benjamin, Shore and Gilchrist (59) for further detail) of which some are vasoactive 521 
(16, 45, 56). Supplements rich in antioxidants have also been shown to improve redox 522 
balance and improve vascular function (44). The reported reduction in [pan-endothelin] 523 
(Figure 5a), with and without elevations in plasma [nitrite] (Figure 2b), may have contributed 524 
to the improved endothelial function and reduced systolic and diastolic BP observed in the 525 
current study. There was also a small additional reduction in both systolic and diastolic BP 526 
after acute BJ compared to acute NDBJ supplementation. This can be explained, at least in 527 
part, by shifts in the oral microbiome reducing capacity following nitrate supplementation 528 
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(33), meaning that the effect could be larger with acute vs. chronic supplementation. This 529 
effect may also have been larger if BP was measured at 2.5 hours after ingestion, to match 530 
peak plasma [nitrite] (68). Previously published studies in clinical populations that have 531 
observed a reduction in BP after BJ supplementation have also not used a true placebo, 532 
meaning that the antioxidant content was unlikely matched between conditions (5, 42), as 533 
was the case in the present study, and thus the effect of antioxidant / polyphenol rich BJ on 534 
BP needs to be examined in more detail and rigour. 535 
4.6 Cytokines and antioxidant enzymes   536 
BJ is rich in antioxidants and polyphenols (58), however  the effect of BJ supplementation on 537 
systemic redox balance and inflammation have not been reported. There is some evidence to 538 
suggest that individuals suffering with Raynaud’s phenomenon have elevated systemic levels 539 
of inflammation and oxidative stress (6, 29). One previous study used exercise as an model to 540 
induce acute oxidative stress and inflammation, and reported no effect of 3 days of BJ (~ 210 541 
mg) on [ROS] or [IL-10] versus an isocaloric placebo in healthy individuals (12). In the 542 
current study, we report that both one day and 2 weeks of supplementation with BJ and 543 
NDBJ increased plasma [IL-10], but did not alter [IL-6]. An increase in plasma [IL-10] 544 
suggests that both BJ and NDBJ induced an anti-inflammatory effect in this population. The 545 
mechanism/s for this effect and whether it would remain after supplementation ceased or if 546 
individuals would need to continue supplementing daily is unclear. Post hoc analysis, in our 547 
study revealed statistical differences in [IL-10] for primary but not secondary RP. Although 548 
we are not powered to detect these changes, future studies should examine the potential 549 
ergogenic of beetroot juice supplementation at different levels of disease severity and in 550 
particular, inflammatory status. Two weeks of supplementation with BJ did not alter the 551 
concentration of markers of oxidative stress (PRDX-4, TRX-1 and SOD3). PRDX-4 and 552 
TRX-1 are endogenous antioxidant enzymes, which are secreted into the extracellular 553 
environment (i.e. plasma) in response to elevated intracellular oxidative stress; whilst SOD3 554 
is an extracellular antioxidant enzyme anchored to the membrane of cells to eliminate 555 
superoxide anions (i.e. ROS) directly within the extracellular space. A growing body of 556 
evidence now supports a role for PRDX, TRX and SOD3 in regulating the inflammatory 557 
response (23, 34, 35). Although these markers were unaltered following 2 weeks of 558 
supplementation in the present study, this does not preclude the possibility that longer-term 559 
supplementation with BJ or NDBJ may reduce these and other markers of oxidative stress 560 
and inflammation in this population. 561 
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4.7 Qualitative interviews 562 
Participants’ accounts support the statistical findings from this study that blood flow 563 
increased in the hands, with one participants stating they felt their “blood vessels open up”. 564 
One participant suggested that they felt ill, which coincides with the reported adverse events 565 
including headaches and hot flushes. It is theoretically possible this may be due to increased 566 
blood flow to the brain (40) and increased skin perfusion (47), which may lead to side effects 567 
in a similar way to organic nitrates (66). Conversely, one participant was happy to 568 
recommend the juice and enjoyed the taste. Two individuals with scleroderma reported 569 
gastrointestinal distress however this may be related to their condition (20). Larger trials are 570 
needed to establish rates of adverse effects following BJ supplementation. 571 
4.8 Strengths, limitations and future work 572 
A strength of this research was its robust experimental design (double-blind, randomised, 573 
crossover trial). Several limitations do, however, warrant discussion. Firstly, the qualitative 574 
interviews were conducted between 2 and 12 weeks following participants’ completion of the 575 
study, which may limit the accuracy of recall in some cases. We may also have missed the 576 
peak BP effects as BP was taken at 1.5 hours after ingestion. The sample size was relatively 577 
small and non-homogenous, including a spread of primary and secondary conditions. As a 578 
consequence, it was not possible to examine differences between these groups to determine 579 
whether one group may potentially benefit more from BJ supplementation. NO 580 
responsiveness and metabolism is known to be reduced in older individuals (51, 63), we 581 
therefore cannot preclude that the effect seen in this study would be larger in a group of 582 
younger individuals with primary RP. A larger definitive trial, examining the efficacy of BJ 583 
supplementation, is therefore needed in individuals with RP. Given these results it appears 584 
that BJ supplementation may indeed offer an inexpensive intervention to improve endothelial 585 
(dys)function in individuals with RP.  586 
587 
5.0 Conclusion  588 
This is the first study to examine the effect of dietary nitrate supplementation on extremity 589 
rewarming, endothelial function and BP in individuals with RP. We show that both BJ and 590 
NDBJ increased blood flow in the thumb following a cold challenge; improved endothelium 591 
dependant and independent vasodilation in the forearm; and reduced systolic and diastolic BP 592 
20 
in comparison to baseline. These effects appear to be linked, at least in part, to reduced 593 
inflammatory markers. Efficacy trials are warranted to verify these findings.   594 
595 
6.0 Acknowledgments  596 
We would like to thank the participants who volunteered to take part in this. We would also 597 
like to thank the National Institute for Health Research Clinical Research Network for 598 
adopting this study onto their portfolio and the research nurses (Rheumatology Department, 599 
Queen Alexandra Hospital, Portsmouth; Paula White and Marie White) who supported 600 
participant recruitment. We acknowledge help with data collection / analysis from Freyja 601 
Haigh. We gratefully acknowledge the funding from the University of Portsmouth and James 602 
White Drinks Ltd. MG has received funding from James White Drinks Ltd for development 603 
of the placebo. All other authors declare no conflict of interest. This research was supported 604 
by the the National Institute for Health Research (NIHR) Leicester Biomedical Research 605 
Centre. The views expressed are those of the authors and not necessarily those of the NHS, 606 
the NIHR or the Department of Health.  607 
608 
7.0 Contribution Statement 609 
AS, HM, JC, ZS, SB, MG, SY and CE designed the research. CE, HM, JC, PG, HM, DW, 610 
AW and AS conducted research. SB, NB and AW provided essential reagents. AS, HM, JC, 611 
CE, SB, NB, AW, PG, HM, HM, DW, analysed data or performed statistical analysis. AS, 612 
CE, SB and ZS wrote the paper. AS had primary responsibility for final content. All authors 613 
read and approved the final manuscript. 614 
615 
616 








3. Bateman RM,  Ellis  CG,  and  Freeman DJ.  Optimization  of Nitric Oxide  Chemiluminescence 623 
Operating Conditions for Measurement of Plasma Nitrite and Nitrate. Clinical Chemistry 48: 570‐573, 624 
2002. 625 





6. Biondi  R,  Coaccioli  S,  Lattanzi  S,  Puxeddu A,  and  Papini M. Oxidant/antioxidant  status  in 631 
patients with Raynaud's disease. La Clinica terapeutica 159: 77‐81, 2008. 632 
7. Braun  V,  and  Clarke  V.  Using  thematic  analysis  in  psychology.  Qualitative  research  in 633 
psychology 3: 77‐101, 2006. 634 








11. Carlström M,  Liu M,  Yang  T,  Zollbrecht  C,  Huang  L,  Peleli M,  Borniquel  S,  Kishikawa  H, 643 
Hezel M, Persson AEG, Weitzberg E,  and Lundberg  JO.  Cross‐talk Between Nitrate‐Nitrite‐NO and 644 




after  a  marathon  and  the  influence  of  an  antioxidant‐rich  beetroot  juice.  Applied  Physiology, 649 
Nutrition, and Metabolism 43: 303‐306, 2017. 650 
13. Cosby K, Partovi K, Crawford J, H, Patel R, P, Reiter C, D, Martyr S, Yang B, K, Waclawiw M, 651 
A,  Zalos G,  Xu X,  Huang K,  T,  Shields H,  Kim‐Shapiro D,  B,  Schechter A, N,  Cannon  III  R, O,  and 652 
Gladwin  M,  T.  Nitrite  reduction  to  nitric  oxide  by  deoxyhemoglobin  vasodiltaes  the  human 653 
circulation Nature Medicine 9: 1498‐1505, 2003. 654 
14. Davey  M,  Eglin  C,  House  J,  and  Tipton  M.  The  contribution  of  blood  flow  to  the  skin 655 





16. Egert S, Bosy‐Westphal A, Seiberl  J, Kürbitz C,  Settler U, Plachta‐Danielzik S, Wagner AE, 661 
Frank  J,  Schrezenmeir  J,  and  Rimbach  G.  Quercetin  reduces  systolic  blood  pressure  and  plasma 662 
oxidised  low‐density  lipoprotein  concentrations  in  overweight  subjects  with  a  high‐cardiovascular 663 






18. Eglin CM, Golden FS, and Tipton MJ. Cold sensitivity  test  for  individuals with non‐freezing 670 
cold injury: the effect of prior exercise. Extreme Physiology & Medicine 2: 1, 2013. 671 
19. Ferreira‐Valente MA, Pais‐Ribeiro JL, and Jensen MP. Validity of  four pain  intensity  rating 672 
scales. PAIN® 152: 2399‐2404, 2011. 673 
22 
20. Forbes  A,  and  Marie  I.  Gastrointestinal complications:  the  most  frequent  internal 674 
complications of systemic sclerosis. Rheumatology 48: iii36‐iii39, 2006. 675 








24. Gilchrist M, Winyard  P,  and  Benjamin N.  Dietary Nitrate  ‐ Good or  bad? Nitric Oxide 22: 684 
104‐109, 2010. 685 
25. Gilchrist M, Winyard PG, Aizawa K, Anning C, Shore A, and Benjamin N.  Effect of dietary 686 








28. Greenstein D, Gupta N, Martin  P, Walker D,  and Kester  R.  Impaired  thermoregulation  in 695 
Raynaud's phenomenon. Angiology 46: 603‐611, 1995. 696 
29. Gualtierotti R, Ingegnoli F, Griffini S, Grovetti E, Borghi MO, Bucciarelli P, Meroni PL, and 697 




31. Holowatz  L,  Thompson‐Torgerson  C,  and  Kenney  W.  Viewpoint:  The  human  cutaneous 702 
circulation as a model of generalized microvascular function. J Appl Physiol. 703 





34. Iversen  MB,  Gottfredsen  RH,  Larsen  UG,  Enghild  JJ,  Praetorius  J,  Borregaard  N,  and 709 
Petersen  SV.  Extracellular  superoxide  dismutase  is  present  in  secretory  vesicles  of  human 710 
neutrophils and released upon stimulation. Free Radical Biology and Medicine 97: 478‐488, 2016. 711 





37. Joris  PJ,  and Mensink  RP.  Beetroot  juice  improves  in  overweight  and  slightly  obese men 717 
postprandial  endothelial  function  after  consumption  of  a mixed meal. Atherosclerosis 231:  78‐83, 718 
2013. 719 








kinetics,  and  muscle  and  cognitive  function  in  older  adults.  American  journal  of  physiology 727 
Regulatory, integrative and comparative physiology 304: 21, 2013. 728 
41. Kenjale AA, Ham KL, Stabler T, Robbins  JL,  Johnson JL, VanBruggen M, Privette G, Yim E, 729 





43. Khan  F,  and  Belch  J.  Skin  blood  flow  in  patients  with  systemic  sclerosis  and  Raynaud's 735 
phenomenon:  effects  of  oral  L‐arginine  supplementation.  The  Journal  of  rheumatology  26:  2389‐736 
2394, 1999. 737 
44. Khan  F,  Ray  S,  Craigie  AM,  Kennedy  G,  Hill  A,  Barton  KL,  Broughton  J,  and  Belch  JJ. 738 
Lowering of  oxidative  stress  improves endothelial  function  in  healthy  subjects with habitually  low 739 
intake  of  fruit  and  vegetables:  A  randomized  controlled  trial  of  antioxidant‐and  polyphenol‐rich 740 
blackcurrant juice. Free Radical Biology and Medicine 72: 232‐237, 2014. 741 
45. Koltuksuz U, Özen S, Uz E, Aydinç M, Karaman A, Gültek A, Akyol Ö, Gürsoy MH, and Aydin 742 
E.  Caffeic  acid  phenethyl  ester  prevents  intestinal  reperfusion  injury  in  rats.  Journal  of  Pediatric743 
Surgery 34: 1458‐1462, 1999. 744 
46. Lara  J, Ashor AW, Oggioni C, Ahluwalia A, Mathers  JC, and Siervo M.  Effects of  inorganic 745 
nitrate  and  beetroot  supplementation  on  endothelial  function:  a  systematic  review  and  meta‐746 
analysis. European journal of nutrition 55: 451‐459, 2016. 747 
47. Levitt  EL,  Keen  JT,  and  Wong  BJ.  Augmented  reflex  cutaneous  vasodilatation  following 748 
short‐term dietary nitrate supplementation in humans. Experimental physiology 100: 708‐718, 2015. 749 
48. Levitt  EL,  Keen  JT,  and  Wong  BJ.  Augmented  reflex  cutaneous  vasodilatation  following 750 
short‐term dietary nitrate supplementation in humans. Experimental physiology 2015. 751 
49. Li  H,  and  Forstermann  U.  Uncoupling  of  endothelial  NO  synthase  in  atherosclerosis  and 752 
vascular disease. Curr Opin Pharmacol 13: 161‐167, 2013. 753 
50. Lundberg  J,  Weitzberg  E,  and  Gladwin  M,  T.  The  nitrate‐nitrite‐nitric  oxide  pathway  in 754 
physiology and theraputics. Nature Reviews Drug Discovery 7: 156‐167, 2008. 755 
51. Minson CT, Holowatz LA, Wong BJ, Kenney WL, and Wilkins BW. Decreased nitric oxide‐and 756 
axon  reflex‐mediated  cutaneous  vasodilation  with  age  during  local  heating.  Journal  of  applied 757 
physiology 93: 1644‐1649, 2002. 758 
52. Moncada  S,  and  Higgs  A.  The  L‐Argenine‐nitric  oxide  pathway.  New  England  Journal  of 759 
Medicine 329: 2002‐2012, 1993. 760 









56. Ochiai  R,  Jokura H,  Suzuki  A,  Tokimitsu  I,  Ohishi M,  Komai  N,  Rakugi  H,  and Ogihara  T. 770 





58. Shepherd  AI,  Gilchrist  M,  Winyard  PG,  Jones  AM,  Hallmann  E,  Kazimierczak  R, 775 
Rembialkowska  E,  Benjamin  N,  Shore  AC,  and  Wilkerson  DP.  Effects  of  dietary  nitrate 776 
supplementation on the oxygen cost of exercise and walking performance in individuals with type 2 777 
diabetes:  a  randomized,  double‐blind,  placebo‐controlled  crossover  trial. Free  Radical  Biology and 778 
Medicine 86: 200‐208, 2015. 779 
59. Shepherd AI, Wilkerson DP, Dobson L, Kelly J, Winyard PG, Jones AM, Benjamin N, Shore 780 










pressure  liquid  chromatography  with  ultraviolet  light  method  detected  the  reduction  of  serum 791 
nitrite/nitrate  levels  after  cold  exposure  in  patients  with  Raynaud’s  phenomenon.  The  Journal  of 792 
dermatology 39: 889‐890, 2012. 793 







and  inflammation  with  vascular  dysfunction  in  ageing:  the  vascular  health  triad.  Age  (Dordrecht, 801 
Netherlands) 35: 705‐718, 2013. 802 
66. Wigley    FM.  Raynaud's  Phenomenon. New  England  Journal  of  Medicine  347:  1001‐1008, 803 
2002. 804 














Figure 1. Participant flow through the trial.  
Figure 2. Mean (SD) plasma [nitrate] (A) and [nitrite] (B) in the baseline, acute nitrate-depleted (acute-
NDBJ), nitrate-rich (acute-BJ) beetroot juice, and chronic nitrate-depleted (chronic-NDBJ) and nitrate-rich 
(chronic-BJ) beetroot juice supplementation conditions (n =  21).  *  P < 0.001 significantly different from 
acute-NDBJ and chronic-NDBJ and baseline. Plasma [nitrate] and [nitrite] were analysed using repeated 
measures ANOVA. Figure 3. Mean ± SD great toe CVC (A), thumb CVC (B), great toe skin temperature 
(C) and thumb skin temperature (D) for baseline (open squares ), acute nitrate-depleted beetroot juice 
(NDBJ) (open circles ), acute (beetroot juice) BJ (closed circles ), chronic NDBJ (closed triangles 
) and chronic BJ (closed diamonds ) supplementation conditions. * P < 0.05 significant difference in 
four places within panel B, 1) baseline to chronic-NDBJ 2) baseline to chronic-BJ, 3) acute-NDBJ and 
chronic-NDBJ, and 4) acute-BJ and chronic-BJ (n = 23). Data was analyzed using 5 × 3 repeated-measures 
ANOVAs (condition [baseline, acute-BJ, chronic-BJ, acute-NDBJ and chronic-NDBJ supplementation] * time 
[pre immersion, 5 min, 10 min]) for mean toe, coldest toe, great toe, mean finger, coldest finger and thumb Tsk, 
thumb and great toe skin blood flows. Figure 4. Data are presented as median and interquartile range (25 and 
75 percentiles) for maximum CVC, area under the curve (AUC). Significant difference is depicted with a * (< 
0.05) and trends with a # (< 0.10). For the endothelial function test, maximum CVC and AUC were analysed 
using repeated-measures ANOVAs (baseline, acute BJ, chronic BJ, acute PL and chronic PL 
supplementation). Where data were not normally distributed Friedman tests were used with Wilcoxon follow 
ups. 
Figure 5. Data are presented as median and interquartile range (25 and 75 percentiles) for maximum CVC, area 
under the curve (AUC). Significant difference is depicted with a * (< 0.05) and trends with a # (< 0.10). For 
the endothelial function test, maximum CVC and AUC were analysed using repeated-measures ANOVAs 
(baseline, acute BJ, chronic BJ, acute PL and chronic PL supplementation). Where data were not normally 
distributed Friedman tests were used with Wilcoxon follow ups. 
Figure 6. Systolic (A) and diastolic (B) diastolic blood pressure for baseline, acute (acute-NDBJ) and 
chronic (chronic-PL) nitrate-depleted beetroot juice (NDBJ) and acute (acute-BJ) and chronic (acute-NDBJ) 
nitrate-rich 
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beetroot juice (BJ) supplementation conditions. Data are presented as mean ± SD * P < 0.05 significantly 
different from corresponding brackets (n = 23). Data were analysed using repeated measures ANOVA.   
Figure 7. Median and IQR (25th and 75th percentiles) for Pan endothelin (A), IL-10 (B), IL-6 (C), SOD3 (D), 
TRX-1 (E) and PRDX-4 (F) at baseline, acute (acute-NDBJ) and chronic (chronic-NDBJ) nitrate-depleted 
beetroot juice (NDBJ) and acute (acute-BJ) and chronic (chronic-BJ) nitrate-rich beetroot juice (BJ) 
supplementation conditions. * P < 0.05 significantly different from baseline, # = trending towards significance 
(P = 0.07) (n = 21). Friedman tests were used to assess main effects and where appropriate, post-hoc tests were 
conducted using pairwise comparisons with least significant differences. 
Table 1. Participant characteristics (n=23). 
Characteristics Mean or % 
Age 64.3  ± 15.3 y
Female 83%





Mixed connective tissues disorder  4.3%
Rheumatoid arthritis  4.3%
Height 1.7 ± 0.1 m 
Mass 64.3 ± 10.5 kg
Baseline systolic BP 134.0 ± 18.6 mmHg
Baseline diastolic BP  83.2 ± 10.2 mmHg
Number of 30+ minutes of exercise per week 4.3 ± 2.5
Portions of fruit and vegetables per day 5.6 ± 2.7 
Mini mental state exam 28.9 ± 0.9
Data presented as mean ± SD or as a % unless otherwise stated from participants who completed the trial. N.B. 
A number of individuals presented with two diseases specifically relating to secondary Raynaud’s Phenomenon. 
Mini mental state exam ranges from 0-30, which we used a cut of 18 to determine capacity to consent.    
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Table. 2. Thermal sensation, thermal comfort and pain in the foot and hand during the cold sensitivity test at 
baseline, nitrate-depleted (PL) and nitrate-rich (BJ) beetroot juice supplementation conditions. Average rewarm 
is the mean over the last 8 minutes of rewarming.  
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Data are presented as means ± SD. 1 = significantly different from baseline (P < 0.05), 2 acute placebo and 















Baseline 21 11.8 ± 4.0 4.4 ± 2.6 7.6 ± 4.3 11.0 ± 2.9
Acute NDBJ 21 12.7 ± 4.2 3.8 ± 2.2 5.4 ± 2.9 9.7 ± 3.1
Acute BJ 21 12.4 ± 4.8 3.7 ± 2.6 5.6 ± 2.4 10.5 ± 3.2
Chronic NDBJ 21 13.3 ± 3.8 4.6 ± 3.2 5.5 ± 3.2 10.5 ± 2.7
Chronic BJ 21 11.9 ± 4.2 3.9 ± 2.3 5.2 ± 2.6 9.7 ± 3.4
Thermal 
comfort
Baseline 21 13.0 ± 5.3 9.1 ± 5.0 11.2 ± 4.1 13.2 ± 3.6 
Acute NDBJ 21 12.6 ± 4.2 7.1 ± 5.41 7.5 ± 4.01 11.3 ± 3.81 
Acute BJ 21 13.0 ± 5.2 7.6 ± 4.4 9.2 ± 3.91  12.1 ± 3.7 
Chronic NDBJ 21 13.1 ± 5.1 7.5 ± 4.3 7.4 ± 3.01 12.2 ± 3.5 
Chronic BJ 21 12.7 ± 5.0 6.6 ± 4.61,2 8.2 ± 4.51 11.1 ± 3.61
Pain
Baseline 20 0.2 ± 0.8 1.0 ± 1.7 1.0 ± 1.7 0.2 ± 0.6 
Acute NDBJ 20 0.0 ± 0.0 0.7 ± 1.3 0.7 ± 1.3 0.2 ± 0.6 
Acute BJ 20 0.2 ± 0.8 0.7 ± 1.3 0.7 ± 1.3 0.3 ± 0.8 
Chronic NDBJ 20 0.0 ± 0.0 0.8 ± 1.7 0.8 ± 1.7 0.9 ± 2.7 




Baseline 21 13.2 ± 2.4 4.1 ± 2.9 6.0 ± 3.6 11.5 ± 2.8 
Acute NDBJ 21 13.8 ± 3.3 3.6 ± 2.2 5.6 ± 2.9 12.1 ± 3.2
Acute BJ 21 13.6 ± 2.5 3.4 ± 2.3 5.8 ± 2.7 12.1 ± 3.9 
Chronic NDBJ 21 13.9 ± 3.4 3.9 ± 3.0 5.1 ± 3.7 11.9 ± 3.2 
Chronic BJ 21 13.7 ± 2.4 3.6 ± 2.2 5.8 ± 2.7 12.2 ± 3.2 
Thermal 
comfort
Baseline 21 13.7 ± 4.5 6.2 ± 4.5 9.3 ± 4.7 13.4 ± 3.8 
Acute NDBJ 21 15.1 ± 4.0 6.8 ± 5.3 8.0 ± 4.3 12.6 ± 3.7 
Acute BJ 21 14.8 ± 3.9 7.3 ± 4.4 8.4 ± 4.1 13.1 ± 3.2 
Chronic NDBJ 21 14.6 ± 4.1 7.2 ± 4.3 6.7 ± 3.9 12.9 ± 3.0 
Chronic BJ 21 15.6 ± 3.5 6.4 ± 4.5 8.4 ± 3.9 13.5 ± 3.5 
Pain
Baseline 20 0.1 ± 0.4 0.6 ± 1.2 0.2 ± 0.6 0.2 ± 0.6 
Acute NDBJ 20 0.0 ± 0.0 0.7 ± 1.3 0.4 ± 1.0 0.2 ± 0.6 
Acute NDBJ 20 0.2 ± 0.7 0.7 ± 1.3 0.4 ± 1.0 0.3 ± 0.8 
Chronic PL 20 0.0 ± 0.0 0.8 ± 1.7 0.5 ± 1.0 0.9 ± 2.7 
Chronic BJ 20 0.1 ± 0.4 0.6 ± 1.2 0.3 ± 0.8 0.2 ± 0.6 
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CVC response to iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP) on the forearm, finger 
and foot in the baseline, acute and chronic nitrate rich (BJ) and nitrate depleted (PL) beetroot juice 
supplementation conditions.  
n ACh Max ACh AUC n SNP Max SNP AUC Tsk (°C)
Forearm
Baseline 18 3.1 ± 1.7 15.3 ± 10.2 16 3.3 ± 1.5 12.7 ± 7.0 29.4 ± 0.3
Acute NDBJ 17 4.4 ± 1.3 20.8 ± 7.9 16 4.1 ± 1.5 17.5 ± 8.23 29.0 ± 0.4
Acute BJ 17 4.9 ± 1.72 21.9 ± 9.4 16 4.0 ± 1.3 14.7 ± 6.3 29.0 ± 0.4
Chronic NDBJ 17 3.7 ± 2.0 15.8 ± 8.1 16 3.0 ± 2.0 11.5 ± 8.4 28.9 ± 0.6
Chronic BJ 17 4.3 ±1.73 18.8 ± 11.1 16 4.7 ± 1.9 1,3 17.6 ± 8.01,2 29.0 ± 0.4
Finger
Baseline 15 2.5 ± 1.9 10.6 ± 9.5 15 1.6 ± 1.0 6.7 ± 4.8 28.4 ± 0.3
Acute NDBJ 15 1.3 (0.8, 2.6) 6.8 (2.8, 9.4) 15 1.2 (0.4, 3.4) 5.7 (1.5, 14.7) 27.1 ± 0.5
Acute BJ 15 1.9 (0.6, 6.1) 6.4 (2.0, 29.5) 15 1.6 (0.7, 4.0) 5.1 (2.6, 16.0) 27.3 ± 0.6
Chronic NDBJ 15 2.9 ± 2.7 13.9 ± 19.1 15 2.2 ± 2.4 9.9 ± 12.3 27.2 ± 0.4
Chronic BJ 15 2.7 ± 2.2 11.4 ± 11.1 15 2.1 ± 1.5 9.2 ± 7.8 27.4 ± 0.4
Foot
Baseline 15 1.7 ± 1.7 6.2 ± 6.9 15 1.1 ± 0.9 3.8 ± 3.2 27.4 ± 0.6
Acute NDBJ 15 3.4 ± 2.8 11.3 ± 9.8 15 1.7 ± 1.8 5.8 ± 4.6 27.0 ± 0.52
Acute BJ 15 2.7 ± 1.1 8.2 ± 4.3 15 1.6 ± 1.2 4.4 ± 3.5 26.7 ± 0.8
Chronic NDBJ 15 2.2 ± 2.1 5.0 (1.4, 12.7) 15 1.8 ± 1.4 5.4 (2.3, 7.4) 26.6 ± 0.6
Chronic BJ 15 3.4 ± 2.6 11.2 (6.0, 19.3) 15 2.5 ± 1.9 6.7 (2.9, 10.3) 26.6 ± 0.6
Data are presented as means ± SD or median and interquartile range (25 and 75 percentiles) for maximum CVC, 
area under the curve (AUC) and skin temperature (Tsk). 
1 = different to nitrate-depleted beetroot juice (PL) at the 
same time point and 2 = different from baseline, 3 = trend (< 0.10) towards difference with baseline. For the 
endothelial function test, maximum CVC, AUC and Tsk were analysed using repeated-measures ANOVAs 
(baseline, acute BJ, chronic BJ, acute PL and chronic PL supplementation). Where data were not normally 
distributed Friedman tests were used with Wilcoxon follow ups. 







